Background: Tumor necrosis factor a (TNF-ca) is often considered the main proinflammatory cytokine induced by lipopolysaccharide (LPS) and consequently the critical mediator of the lethality assocated with septic shock. Materials and Methods: We used mice carrying a deletion of both the lymphotoxin a (LT-a) and TNF-a genes to assess the role of TNF in the cytokine cascade and lethality induced by LPS.
INTRODUCTION
The cytokine network is defined by cascades of cytokines, positive and negative feedbacks, autocrine effects, and synergistic actions. Knowledge of this network has been essentially achieved by the use of recombinant cytokines and specific antibodies. More recently, transgenic and knockout animals have been successfully employed to further characterize the relative contribution of each cytokine. Tumor necrosis factor a (TNF-a) is considered a key cytokine within the network of pro-and anti-inflammatory cytokines. It has been well established that in vitro TNF-a can trigger its own production (1) as well as the release of interleukin 1 (IL-1) (1), IL-6 (2), (3), IL-10 (4), macrophage colony stimulating factor (5) , and many other cytokines by different cell types, including monocytes and macrophages, fibroblasts, endothelial cells, and epithelial cells. Similarly, in vivo, TNF-a is able to induce in the bloodstream the appearance of IL-1 (6) , (7) , (8) , (9) , IFN-,y (10) , and other cytokines.
Endotoxins (lipopolysaccharide; LPS) from gram-negative bacteria are potent TNF-a inducers. Following LPS or bacteria injection, the peak of circulating TNF occurs rapidly within 90 min (11) (12) (13) (14) . The TNF-a peak precedes that of IL-1, IL-6, and IL-8. TNF-a mRNA levels peak in vivo at 15 min after LPS injection and at 1 hr in in F. Amiot et al.: LPS Lethality in TNF-Deficient Mice 865 vitro assays (1 5) . This has led to the proposal that TNF-a could orchestrate the production of other cytokines. This model has been supported by experiments with anti-TNF-a. For example, in the baboon model, in which a lethal injection of Escherichia coli led to the appearance of circulating TNF-a, IL-1iB, and IL-6, pretreatment of the animals with a monoclonal antibody anti-TNF-a 2 hr before the E. coli infusion significantly reduced the levels of any detectable cytokines in plasma (16) . This observation has been confirmed following injection of endotoxin and gram-positive bacteria (17) (18) (19) and extended to IL-8 (20) . Similar findings were obtained using soluble TNF receptor, soluble TNF receptor-Fcy chimeric molecule, and two TNF receptors bound covalently to polyethylene glycol to neutralize TNF-a (21) (22) (23) .
However, not all in vivo experiments support a central role for TNF-a in the induction of the cytokine cascade. This is particularly the case for interleukin-la (24) , circulating 25) , and interferon gamma (IFN-,y) (24, 26) . More- over, LPS can probably directly induce the production of several cytokines. For example, in a whole-blood assay, suboptimal doses of LPS did not lead to the release of detectable TNF-a, but they induced significant amounts of (27) . In addition, different in vitro as well as in vivo inhibition of TNF by either specific antibodies, pentoxifylline, or adenosine kinase inhibitor failed to modify the levels of other cytokines, including IL-la, IL-1,B, and IL-6 (28-31).
Thus, even within the simple model of the response to LPS, the role of TNF-a in the induction of the cytokine cascade has not been clearly established. To further analyze the role of TNF-a in this cascade, we investigated the production of various cytokines in mice that were rendered deficient for the lymphotoxin-a (LT-a) and TNF-a genes (32, 33) . We studied the in vitro LPS activation of peritoneal macrophages and in vivo levels of circulating cytokines following LPS injection.
In conjunction with a central role for TNF-a in the cytokine cascade, and on the basis of the pioneering work of Cerami's group (34, 35) using specific anti-TNF-a antibodies, it has been proposed that TNF is a major actor responsible for the lethality in endotoxin shock in animal models as well as in models of bacteria-induced lethality (17, 19, 36, 37) . However, the galactosamine model of septic shock has often been employed to demonstrate the beneficial effects of neutralizing TNF-a. Although LPS-induced lethality is essentially mediated by TNF in this model (38) , it may not be the case in other models. For example, carrageenan-sensitized mice were not protected by anti-TNF antibodies against a lethal dose of LPS (39) . In addition, p55 TNF receptor-deficient mice were insensitive to the lethal effect of LPS in galactosamine-injected mice but were as sensitive as wild-type animals to lethal doses of LPS in the absence of galactosamine (40) . Furthermore, the absence of any beneficial effects of treatment with monoclonal anti-TNF-a antibodies or soluble receptor chimeric molecules in septic patients (41, 42) illustrated that blocking TNF-a may not be sufficient for preventing death in these patients. Thus it is of interest to analyze the resistance of LT-a/TNFa-deficient mice when treated with lethal doses of LPS in the absence of any galactosamine treatment.
MATERIALS AND METHODS

Mice
The generation of LT-a/TNF-a-deficient mice has been described elsewhere (33) . The animals of the three genotypes used in this study were of a comparable 129sv X C57BL/6 genetic background. Mice (Fig. 3) , with no death occurring after this period. In wild-type mice of 129sv x C57BL/6 genetic background, an LD50 of 600 jig was observed (Fig. 3A) . In homozygous LT-a/ TNF-a-/-mice, the same LD50 of 600 ,tg was observed (Fig. 3C) (Fig. 4A) . In mutant mice, doses of 2 and 10 mg/kg conferred an even better protection (Fig. 4B) . Thus an inhibitor of cytokine production can more easily protect mutant mice against LPS-induced lethality, confirming both the implication of the other cytokines in their death and the importance of TNF in the death of wild-type mice.
these results on long-term survival is the observation that a major role for TNF was apparent in the death kinetics. In wild-type mice, as is usually observed, all deaths occurred during the first 3 days (Fig. 3A) . (45) . Finally, the effects of anti-TNF treatment on the levels of circulating IL-10 (9,25) and IFN-,y seemed to depend on the nature of the stimuli used (i.e., LPS, whole gramnegative bacteria, Streptococci, anti-CD3) (24, 26) . In a recent report on TNF-a-/-mice, Marino et al. (46) did not find any significant difference between mutant and wild-type animals in terms of IL-13, IL-6, IL-10, and IFN-,y production. The differences between this study and ours may reflect either the exact nature of the deletion (TNF-a versus LT-a/TNF-a) or the route of LPS administration. Furthermore, the use of a larger number of mice in our study is instrumental in establishing the significance of our observations. In summary, our results conclusively establish that the presence of the TNFs is not required for the induction of IL-1, IL-6, and IL-10 by LPS. Nevertheless, TNFs do affect the cytokine cascade, mostly by modulating the later phase of expression. The decrease in IL-6 levels after the initial peak, the late peaks of IL-Ia and IL-1 13, and the persistence of circulating IL-10 in knock-out animals as compared with wild-type mice suggest that regulatory loops involving TNFs may affect cytokine production. If the expression of a cytokine is in part controlled by a positive regulatory loop associated with TNFs, its expression in LTa/TNF-a-deficient mice should be reduced during the later phase of induction. Thus the low levels of IL-6 at 3 hr and 6 hr 30 min may be directly due to the absence of TNF, which is known to induce the production of IL-6, as well as to the reduced levels of TNF-inducible regulatory mediators known to enhance IL-6 production such as prostaglandin E2 (47) , thrombin (48), platelet-activating factor (PAF) (49), leukotriene B4 (50) , and IL-2 (51). Conversely, if there is a negative regulatory loop associated with TNF, the expression in mutant mice of the corresponding cytokine should be increased during the later phase. This could be case for the enhancement of IL-I observed at 3 hr or for the maintenance of high levels of IL-10. This could involve heat shock proteins known to limit IL-I production (52) and corticoids that inhibit IL-1 (53) as well as IL-10 production (54). The enhancement of IL-10 at 3 hr in deficient mice injected with LPS is in agreement with the observations obtained with anti-TNF treatment (55), but this was not observed in TNFa-/-mice (46) . Thus the network of regulations taking place during the cytokine cascade provide multiple mechanisms for the control of the kinetics of cytokine expression. As illustrated above, the injection of LPS initiates a complex pattern of mediators and regulatory loops involving many cell types and tissues. As macrophages are a major source of cytokines upon activation by LPS, it was of interest to investigate the contribution of TNF-a in the production of IL-la, IL-1f, and IL-6 in this cell population. The in vitro analysis of peritoneal macrophage-derived cytokines demonstrates a clear involvement of TNF-a in the production of these cytokines. A lower production of IL-la, IL-1f, and IL-6 was observed in both early (4 hr) or late (18 hr) cultures from deficient mice. These results are in agreement with the fact that TNF-a can trigger the production of these cytokines by macrophages (1, 2, 4, 5, 8 production. In cell cultures, as in the in vivo studies, the use of TNF inhibitors has provided divergent results. Inhibition of TNF by specific antibodies failed to modify the levels of released IL-la, IL-13, and IL-6 in human whole-blood assays upon activation by LPS (28, 56) (29, 30) . Finally, metalloproteinase inhibitors that prevent TNF processing did modify the release of IL-1,B, IL-6, or IL-8 (57, 58) . Further studies are required to fully analyze the reasons for the low capacity of peritoneal macrophages from LT-a/TNF-a-deficient mice to produce IL-1 and IL-6. It might reflect different macrophage subpopulations, as deficient mice possess profiles of leukocytes different from those of wild-type animals (32), or different levels of receptor expression, such as CD14. However, heterozygous mice exhibit only very subtle differences from wild-type animals in their cell populations; nonetheless, a reduction of cytokine expression was observed in heterozygous macrophage cultures. Altogether, these in vitro patterns, which are quite different from those obtained in vivo, confirm that the in vivo situation following LPS injection is not a simple reflection of macrophage activation.
TNF and LPS-Induced Lethality For more than a decade, TNF has been considered a major actor in LPS-induced lethality and tissue injury. These conclusions were reached following experiments in animals models in which injection of anti-TNF (17, 19, (34) (35) (36) (37) or soluble TNF receptors (21, (59) (60) (61) protected the animal against endotoxin-induced shock or gram-negative bacteriemia. Furthermore, injection of TNF was able to mimic most of the deleterious effect associated with LPS challenge or gram-negative bacteria infection. However, the use of galactosamine in some animal models, the differences in protection as a function of the nature of the infectious agent (18, 62, 63) , and the fact that blocking TNF in human sepsis did not lead to significant improvement (41, 42) has dampened the optimistic concept that blocking TNF would be sufficient for preventing death and organ injury in sepsis patients.
Although we and others have previously shown that LT-a/TNF-a-deficient animals are highly resistant to LPS-induced shock in the galactosamine model (33, 64) , we now report that in the absence of galactosamine treatment, the LD50 of LPS is similar in wild-type and LT-a/ TNF-a-deficient mice (i.e., 600 ,ug). It is worth noting that histological analysis of the tissues (lung, adrenal, kidney, liver, gut) sampled shortly before death did not reveal any significant differences between wild-type and knockout animals (data not shown). While these observations definitively establish that LPS -induced shock can be lethal in the absence of TNF, we have also obtained indications that TNF contributes to the severity of LPS-induced shock. Specifically, the marked difference in the death kinetics of wild-type and homozygous mutant mice indicates that TNF is required for the rapid death observed in LPS-treated wild-type mice. In addition, although the LD50 is identical in both groups, 1 mutant mice out of 10 survived at the two highest doses (1200 and 1600 jig), suggest- ing that 100% lethality could be difficult to achieve in the absence of TNF. Similarly, Marino et al. (46) showed that TNFa-/-mice appeared somewhat more resistant to the lethal effect of LPS. We have previously reported (33) that, because of the regulation of TNF production, the phenotype of heterozygous mice challenged with high doses of LPS could be more similar to that of homozygous mutants than to that of wild-type mice. This is again apparent in the present lethality study, as both the delayed death kinetics and the survival of a few mice at the highest doses were observed with heterozygous mice.
In mutant mice, the LPS-induced cytokine cascade still has an important proinflammatory component. Because IL-1, leukemia inhibitory factor (LIF), macrophage migration inhibitory factor (MIF), and IFN-,y have overlapping activities with TNF, they could contribute to the deleterious effects following LPS injection. Indeed, in wild-type mice, blocking IL-I with IL-I receptor antagonist (65) or passive immunization against LIF (66) , MIF (67) , and IFN--y (10) protects against LPS-induced mortality. Furthermore, in addition to cytokines, the blocking of several other mediators (including PAF, tissue factor, anaphylatoxins, nitric oxide, prostaglandins, or leukotriene) has also been shown to be beneficial in animal models, indicating the multiplicity of potential mediators of LPS-induced lethality. CNI 1493 is a translation inhibitor of several proinflammatory cytokines, including TNF-a and IL-1 (44, 68) , which can protect mice from the lethality induced by LPS alone (69) . The fact that LT-a/TNF-a-deficient mice could be protected with lower doses of CNI-1493 than those required by wild-type mice and that death in deficient mice occurs later than in wild-type mice confirms that although other mediators can substitute for TNFs, LPS-induced shock is less severe in mutant than in wild-type mice.
Our data are in agreement with previous reports on TNF receptor (TNFR) knock-out mice. In the absence of galactosamine, LPS-induced lethality in p55 TNFR and p75 TNFR-deficient mice was similar to that in wild-type animals, whereas in the galactosamine model, p55 TNFR-/-but not p75 TNFR-/-mice were protected (40, 70) . This illustrates the importance of the model and suggests that the claim that p55 TNFR-/-mice are resistant to endotoxin shock might be misleading (71) . Nevertheless, transgenic mice for a fusion protein (p55 TNFR-Fc'y3) have been reported to be resistant to endotoxininduced shock in the absence of galactosamine (72) . However, in this study, comparisons between wild-type and transgenic mice were only performed at a unique dose of LPS (LD50 = 250 ,tg in this model).
LT-a/TNF-a-deficient animals are important tools for analyzing the contribution of TNF that circumvent the difficulties inherent to the use of pharmaceutical reagents. However, the specific features of these knock-out mice should be kept in mind when trying to transpose the results to normal situations, as the absence of secondary lymphoid organs (32, 64) and hyperleukocytosis create a biological context that differs from normal ones. Nevertheless, the observation that LPS can induce lethal shock in these deficient animals further suggests that caution should be taken when considering TNF as a unique target for future sepsis therapy.
